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Objective. Osteoarthritis (OA) is a common chronic condition in older individuals, but its association with other 
chronic conditions is largely unknown. This study aimed to systematically review the literature on comorbidities in 
individuals with OA compared to those without.
Methods. We searched 4 databases for observational studies on comorbidities in individuals with OA. Studies of 
OA only or in comparison with non- OA controls were included. The risk of bias and study quality were assessed using 
the Newcastle- Ottawa Scale. The prevalence of comorbidities in the OA group and the prevalence ratio (PR) and 95% 
confidence interval (95% CI) between OA and non- OA groups were calculated.
Results. In all, 42 studies from 16 countries (27 case- only and 15 comparative studies) met the inclusion criteria. 
The mean age of participants varied from 51 to 76 years. The pooled prevalence of any comorbidity was 67% 
(95% CI 57–74) in individuals with OA versus 56% (95% CI 44–68) in individuals without OA. The pooled PR for any 
comorbidity was 1.21 (95% CI 1.02–1.45). The PR increased from 0.73 (95% CI 0.43–1.25) for 1 comorbidity to 1.58 
(95% CI 1.03–2.42) for 2, and to 1.94 (95% CI 1.45–2.59) for ≥3 comorbidities. The key comorbidities associated with 
OA were stroke (PR 2.61 [95% CI 2.13–3.21]), peptic ulcer (PR 2.36 [95% CI 1.71–3.27]), and metabolic syndrome 
(PR 1.94 [95% CI 1.21–3.12]).
Conclusion. Individuals with OA are more likely to have other chronic conditions. The association is dose- 
dependent in terms of the number of comorbidities, suggesting multimorbidities. Further studies on the causality of 
this association and clinical implications are needed.
INTRODUCTION
Osteoarthritis (OA) is by far the most common form of arthritis 
and is a major cause of pain and disability in older individuals (1). 
It is a common, complex disorder with multiple genetic, constitu-
tional, and environmental risk factors (2). The presence of multiple 
chronic conditions in a single individual causes higher mortality, 
increased hospitalization, impaired physical and mental health, 
worse disease outcome, and poorer quality of life (3,4). The coex-
istence of chronic conditions with OA is also very common, espe-
cially in the later decades of life (5,6). For example, according to 
the Centers for Disease Control and Prevention, >30% of individ-
uals with diabetes mellitus and heart disease have OA (7).
Most literature on OA comorbidity was published in the 
last 3 years. The review articles focused on the distribution and 
impact of individual chronic conditions such as cardiovascular 
diseases, diabetes mellitus, and depression in OA (8–11). Even 
though  comorbidity was discussed as a concept in the 1960s, 
only in 1996 was a distinct definition first suggested to differen-
tiate comorbidity (implying an index disease with mechanistically 
linked additional conditions) and multimorbidity (implying any 
co- occurrence of medical conditions) within an individual (12). 
Comorbidity research in OA is still at a preliminary stage, and the 
evidence is yet to be accumulated.
A systematic review on OA reported worsening of pain and a 
decline in functional activities among individuals due to the pres-
ence of other chronic conditions (13). Clinically, comorbidities in 
OA create greater challenges for management. The number and 
pattern of different comorbid conditions determine the severity 
and burden in patients with multimorbidities (14,15). However, 
except for shared risk factors such as aging and obesity, little is 
known about biologic plausibility to explain the concurrence of OA 
and associated comorbidities (16,17). According to the European 
League Against Rheumatism (EULAR) and the National Institute 
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for Health and Care Excellence, the diagnosis and management 
of specific comorbidities and understanding their pattern in OA 
are important and are recommended for best practice (18,19). An 
Arthritis Research UK report on multimorbidity in OA also highlight- 
ed the importance of understanding the presence of multiple 
comorbidities with OA for formulating a patient- centered man-
agement plan (20). This study aimed to systematically review the 
current literature on the comorbidities in OA, specifically, the risk 
(prevalence or incidence) of comorbidities in individuals with OA 
compared to those without OA.
MATERIALS AND METHODS
Search methods and sources. A protocol adhering to 
the Preferred Reporting Items for Systematic Review and Meta- 
Analysis 2015 statement was designed and registered online with 
PROSPERO. Medline, PubMed, Embase, and Scopus databases 
were used to identify studies conducted in any country between 
January 1, 1995 and December 31, 2017. Additionally, “comor-
bidity in OA” was searched in the Google Scholar search engine, 
and the first 1,000 articles were screened for inclusion. The com-
plete search consisted of searches for OA (any joint), searches for 
comorbidities, and searches for observational studies. The 3 search 
strategies were then combined using AND to generate citations. 
The details of the search strategies can be seen in Supplementary 
Appendix A, available on the Arthritis Care & Research web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/acr.24008/ abstract. 
In addition, websites of international societies dealing with arthri-
tis such as EULAR, the American College of Rheumatology, and 
Osteoarthritis Research Society International were searched 
(18,21,22). References within systematic reviews and review arti-
cles were also read for additional relevant original articles.
Selection criteria. All types of observational studies (with 
or without a non- OA control) documenting prevalence or inci-
dence and the risk ratio of OA comorbidity were included in the 
study. We defined comorbidity as the presence of any concurrent 
chronic condition in individuals with OA (as an index disease).
Studies included individuals with OA diagnosed by a physi-
cian through physical examination or radiographic findings. OA 
was the primary exposure, and outcomes were the presence of 
any comorbidities. Other comparisons included studies compar-
ing the prevalence/incidence of comorbidities in OA with non- OA 
controls (comparative) and studies of comorbidities in individuals 
with OA (case- only).
According to the above criteria, all studies identified by title 
and abstract were gathered, and duplicates were removed. 
Potentially relevant articles were selected through initial title and 
abstract screening by 2 authors (SS and AS) independently. Any 
disagreement was discussed with a third author (WZ). The full text 
copies of these relevant articles were then retrieved. We retained 
articles that studied the prevalence of other chronic conditions in 
individuals with OA. Full texts of potentially suitable articles were 
further screened for inclusion (SS). Disagreement in the screening 
of full texts was resolved by a third reviewer (WZ). There was no 
language limitation. We used Endnote for screening of articles, 
and data extraction was done without using any software.
Quality assessment. One reviewer (SS) independently 
assessed study quality based on items in the Newcastle- Ottawa 
Scale (NOS) checklist (23). Any concern on quality scoring was 
decided in consultation with another reviewer (AS or WZ). The 
NOS tool has a scoring scale under 3 sections: participant selec-
tion and representativeness, comparability of study groups, and 
assessment of outcome or exposure. The quality score is based 
on a star system (range 0–9 stars for case–control and cohort 
studies and 0–10 for cross- sectional studies), with a higher score 
representing better methodologic quality.
Data extraction. A customized data extraction form was 
used to extract data from each study. For each included study, 
we collected the following information: authors and publication 
year, title and journal, study country and location (urban or rural), 
study design, sampling method (random or nonrandom), sample 
size, sample characteristics such as age and sex, the number of 
conditions included, methods of comorbidity measurement, and 
prevalence (overall and group specific for each comorbidity).
Outcome. The primary outcome was the risk (prevalence) 
of comorbidities in individuals with OA (cases) versus those with-
out OA (controls), and secondary outcomes included the types of 
comorbidities associated with OA. The risk of having the comor-
bidity between OA and non- OA controls was estimated through 
the prevalence ratio (PR), separately for all comparative studies 
and for age- and sex- matched/adjusted comparative studies. 
For cohort studies, the prevalence of comorbidities reported at 
baseline was included for the estimation because in these studies 
comorbidity was not reported as the outcome.
SIGNIFICANCE & INNOVATIONS
• This is the first systematic review of the current 
literature on comorbidities in osteoarthritis (OA), 
with an extensive list of the conditions.
• In total, 67% of individuals with OA have at least 1 
other chronic condition, which is 20% higher than 
for those without OA.
• There was a graded effect in terms of the risk of 
having 1, 2, and ≥3 comorbidities in individuals with 
OA compared to those without.
• In individuals with OA, the systems most likely to be 
affected by comorbidities are upper gastrointesti-
nal, psychological, cardiovascular, and endocrine.
• Stroke, peptic ulcer, and metabolic syndrome are 
the most common comorbidities.
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Statistical analysis. Descriptive characteristics of the 
studies are expressed as means/medians and/or frequencies, as 
appropriate, depending on the variables. For comorbidity count, 
we used the median because of wider variation in the list of the 
diseases across the studies. Heterogeneity between studies 
was measured using the I2 (%) and Q test (P value) (24,25). Pub-
lication bias was assessed using funnel plots and Egger’s test, 
with statistical significance being conferred to a P value less than 
0.05 (26). For heterogeneity, I2 above 75% was considered as 
wider heterogeneity, demanding careful interpretation of the find-
ings (25). Prevalence and PR and 95% confidence intervals (95% 
CIs) were calculated wherever possible for each comorbidity. The 
PR was chosen over odds ratio (OR) because we had prevalence 
data for both OA cases (exposure) and non- OA controls (non-
exposure). In this scenario, PR is recommended over OR to min-
imize the overestimation of the relative risk (27). For prevalence 
estimation, subgroup analysis was done according to the study 
design (cross- sectional, case–control, and cohort). For PR, how-
ever, only 1 article had a different study design from the others, 
thus not allowing us to perform the subgroup analysis as per the 
study design. Therefore, for the PR estimation, subgroup analy-
sis was done as per the NOS. We used the median NOS score 
of 6 as a cutoff for grouping the studies. To remove the impact 
of age and sex, the association of disease- specific and system- 
specific comorbidities analysis was done for all the comparative 
studies and for age- /sex- matched control comparative studies. 
The results across different studies were pooled using the ran-
dom effects meta- analysis Metaprop module (28), an additional 
function of Stata software, version 15 (29), and Revman software, 
version 5.3 (30).
RESULTS
Search results and study qualities. The initial search 
yielded 70,014 articles from 4 databases. After removal of dupli-
cates, 48,661 remained, of which 1,091 appeared relevant after 
title screening. Abstract reading confirmed 56 relevant articles 
and full- text articles that were fully assessed. In all, 42 articles met 
the inclusion criteria (Figure 1). On the quality assessment scale 
(maximum of 10) for cross- sectional studies (n = 33), the aver-
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta- Analyses flow chart of study selection. OA = osteoarthritis.
 
Excluded: 15 
OA as not an index disease (n = 3) 
Conference abstracts (n = 11) 
Study protocol (n = 1) 
Total citaons retrieved (n = 70,014)
Scopus (n = 12,247) 
EMBASE (n = 17,010) 
Medline (Ovid) (n = 19,408) 
PubMed (n = 21,349)
Records aer duplicates removed 
(n = 48,661) 
Records screened for tle and 
abstract (n = 1,091) 
Arcles assessed for eligibility based 
upon tle and abstract (n = 71) 
Records excluded (n = 47,570)
Not relevant  
Excluded: 1,020 
Non-relevant (n = 889: OA not an index 
disease, mulmorbidity)  
Post-surgical OA study (n = 131) 
Arcles eligible for full 
 review (n = 56) 
Identification 
Eligibility screening 
Included 
Records 
idenfied 
through 
cross 
reference 
and 
citaons = 8 
Arcles included in data 
synthesis (n = 42) 
Excluded: 14 
Concept note/editorial (n = 4) 
Duplicaon of study findings (n = 5) 
No clinical comorbidity (n = 5) 
Duplicates excluded (n = 21,353)
SWAIN ET AL 994       |
age score was 5.44 (median 6), and of those, 22 studies had 
≥5 stars (31–52). Five case–control and 4 cohort studies had an 
average score of 5.22 (range 0–9), with 6 studies (6,33,53–56) 
having ≥5 stars (see Supplementary Table 1, available on the 
Arthritis Care & Research web site at http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24008/ abstract). References 51–92 are 
in Supplementary Appendix B, available on the Arthritis Care & 
Research web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.24008/abstract.
Study characteristics. Of the 42 included studies, 15 
compared comorbidities between individuals with OA and those 
without (comparative studies), whereas 27 examined comor-
bidities in individuals with OA only (case- only studies). These 
included 3 case–control studies (6,57,58), 6 cohort studies (53–
56,59,60), and 33 cross- sectional studies that explored comor-
bidity in  individuals with OA (1,5,31–52,61–70) (Table 1). We used 
the baseline comorbidity information from the cohort studies. 
Thus, we could calculate prevalence only for the comorbidities. 
Twelve stud ies were from the US (32,34–40,53,57,63,65), 9 
from the Netherlands (1,33,41–44,54,55,59,60), 4 from the UK 
(6,45,46,66), 2 each from Finland (47,48), Japan (49,56), and Italy 
(61,67), and 1 each from Canada (50), Hong Kong (5), Spain (68), 
Australia (51), South Korea (52), Germany (31), Turkey (62), India 
(69), Brazil (70), Iraq (58), and Latin America (64). Twelve stud-
ies were community- based (6,40,45,47,49,51–53,55,56,65,66), 
2 were based on national insurance data (32,57), and 28 were 
hospital- based studies. Eleven studies collected information on 
knee OA (5,37,49,52,53,56–58,62,68,69), 2 were on hip OA 
(47,63), 14 were on both knee and hip OA (1,6,33,39,41,42,45, 
54,55,60,66,67,71), and there was 1 each on ankle (35), hand 
(43), and hip/knee/hand OA (61). Of 15 comparative studies, 12 
Table 1. Characteristics of included studies*
Characteristic
Comparative studies 
(OA versus non- OA)
Case- only studies 
(OA only)
Studies 15 27
Study participants 773,592 832,423
Age, mean (range) years 60.1 (50.8–76.1) 63.9 (54.1–74.0)
Women, % (95% CI) 53.0 (35.0–70.0) 63.0 (57.0–69.0)
Body mass index, mean (range)† 27.3 (24.0–29.8) 
(3 studies)
27.0 (22.0–31.3) 
(17 studies)
Obesity prevalence, % (95% CI)† 53.4 (42.7–64.1) 
(7 studies)
31.9 (21.6–42.3) 
(18 studies)
Comorbidities assessed, median (IQR)‡ 6 (4–24) 
(15 studies)
13 (8–15) 
(27 studies)
OA site
Knee 5 6
Hip 0 2
Ankle 1 0
Both knee and hip 3 11
Hand 0 1
Any joint 5 6
Hand, hip, and knee 0 1
Not given 1 0
Methods of comorbidity measurement
Charlson Comorbidity Index 0 2
Chronic Illness Rating Scale 1 3
Simple count 10 16
Functional comorbidity assessment 1 0
Self- assessed comorbidity questionnaire 0 1
Three methods 0 1
Not mentioned 3 4
Study settings
Community- based 7 5
Hospital- based 6 22
Insurance data 2 0
Methods of OA diagnosis
Physician diagnosed 6 18
Self- reported 3 1
Radiographic 1 0
Physician diagnosed and radiographic 5 8
* Values are the number unless indicated otherwise. OA = osteoarthritis; 95% CI = 95% confidence 
interval; IQR = interquartile range. 
† Information on the variable was available on the number of studies. 
‡ Number of comorbidities assessed in the studies. Information on the variable was available on the 
number of studies. 
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had controls minimally matched for age and sex of OA cases. In 
the included studies, OA was diagnosed in the following ways: 
clinician assessment without radiographic findings (n = 24), clini-
cal assessment with radiographic diagnosis (n = 13), self- reported 
physician- given diagnosis (n = 4) (40,45,51,65), and radiographic 
findings alone (n = 1) (62). Details of the study characteristics are 
provided in Supplementary Table 2, available on the Arthritis Care 
& Research web site at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24008/ abstract.
The mean age of the study participants varied from 50.8 
years to 76.1 years across studies. The sample size of the 
included studies ranged from 91 to 237,172 (40,49) and included 
both men and women, except 1 study that had only women (56). 
The detailed demographic information (age, sex, body mass 
index, and obesity) is shown in Table 1.
Prevalence of comorbidities. Of 42 included studies, 
15 case- only studies and 8 comparative studies had data on 
the comorbidity count for analysis. The pooled prevalence of any 
chronic condition in all studies among individuals with OA was 
66% (95% CI 58–74). In OA cases, 29% of participants had a 
single comorbidity, 25% had 2, and 24% had ≥3. Further sub-
group prevalence across the study design is shown in Figure 2. 
High heterogeneity was observed across studies. Technical details 
of the data extraction are provided in Supplementary Tables 3 
and 4, available on the Arthritis Care & Research web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/acr.24008/ abstract.
The leading systems in terms of pooled prevalence in individ-
uals with OA were cardiovascular (35%), musculoskeletal (34%), 
neurologic (30%), and upper gastrointestinal (19%). The lead-
ing chronic conditions reported among individuals with OA were 
hypertension (50% [95% CI 36–57]), dyslipidemia (48% [95% CI 
14–66]), and back pain (33% [95% CI 11–37]), followed by thy-
roid disorder (26% [95% CI 6–68]) and depression (17% [95% 
CI 12–22]). The proportion of chronic conditions was reported to 
be higher in case–control and cross- sectional studies compared 
to cohort studies (Figure 3). Details of the prevalence across the 
study designs are given in Supplementary Tables 5 and 6, available 
on the Arthritis Care & Research web site at http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24008/ abstract. All the included stud-
ies were cross- sectional in nature except for 2 studies.
Comparison between individuals with and with-
out OA. Forest plots for PR and 95% CI between OA and the 
number of chronic conditions in comparative studies are shown 
in Figure  4. Eight studies reported the prevalence of comor-
bidities in individuals with OA and in age- and sex- matched 
controls, which were used to estimate PR for matched studies 
(6,34,44,45,49,56,64,65).
The pooled PR for any comorbidity in studies matched for 
age and sex was 1.21 (95% CI 1.02–1.45; I2 = 100%; P < 0.001) 
(Figure 4). The PR increased from 0.73 (95% CI 0.43–1.25) for 1 
comorbidity to 1.58 (95% CI 1.03–2.42) for 2, and to 1.94 (95% 
CI 1.45–2.59) for ≥3 comorbidities in OA compared with individ-
uals without OA (Supplementary Figure 1, available on the Arthri-
tis Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.24008/abstract). Subgroup analysis was done 
for the studies according to the NOS score (Figure  4). Funnel 
plots for the studies are given in Supplementary Figure 2, avail-
able on the Arthritis Care & Research web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/acr.24008/ abstract, and Egger’s 
test reported nonsignificant publication bias (P = 0.72).
The risks for having system- specific comorbidities in age- 
and sex- matched/adjusted studies among individuals with OA 
Figure 2. Prevalence of the number of any comorbidities in individuals with osteoarthritis across the study design. Number of studies in each 
group: Any Comorbidity: total (21), cross- sectional (16), case–control (1), cohort (4); One Comorbidity: total (18), cross- sectional (13), case–
control (2), cohort (3); Two Comorbidities: total (16), cross- sectional (12), case–control (2), cohort (2); Three or more Comorbidities: total (14), 
cross- sectional (10), case–control (2), cohort (2).
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were significantly high for upper gastrointestinal disorder (PR 
2.36 [95% CI 2.31–2.41]), psychological conditions (PR 1.75 
[95% CI 1.20–2.54]), and cardiovascular disease (PR 1.56 [95% 
CI 1.34–1.86]) compared to individuals without OA. For specific 
diseases, the risk of stroke was 2.61 (95% CI 2.13–3.21) times 
higher among individuals with OA compared to those without OA, 
followed by peptic ulcer (PR 2.36 [95% CI 1.71–3.27]) and meta-
bolic syndrome (PR 1.94 [95% CI 1.21–3.12]) (Table 2).
DISCUSSION
To our knowledge, this is the first systematic review of the liter-
ature to examine the evidence of an extensive list of comorbidities 
in OA. A total of 42 studies from 16 countries were included. The 
key findings are: 1) 67% of individuals with OA had at least 1 other 
chronic condition, a level 20% higher than for those without OA, 2) 
there was a graded effect in terms of the risk of having 1, 2, and 
≥3 comorbidities in individuals with OA compared to those without, 
3) the systems most likely to be affected by comorbidities in indi-
viduals with OA were upper gastrointestinal, psychological, cardio-
vascular, and endocrine, and 4) stroke, peptic ulcer, and metabolic 
syndrome were the most common comorbidities in OA.
Studies on multimorbidity from both the developed and 
developing countries reported OA as a leading chronic condition 
(14,15,72,73). The risk of having any comorbidities in OA was 
reported to be 2.35 times higher in the UK general practices pop-
ulation (46), and the risk for multimorbidity was 3 times higher in 
the Australian population compared to a non- OA group (51). The 
stronger association of the number of comorbidities in OA indi-
cates the existence of the problem of multimorbidity among these 
individuals. Besides the number, a pattern of chronic conditions 
in OA influences management decisions. Comorbidities increase 
the complexity of care through increased exposure to medi-
cation and other chronic conditions. However, the relationship 
of these factors with the comorbidities is yet to be discovered. 
The association with multiple chronic conditions requires further 
research to explore the pattern and causality of comorbidities in OA.
However, the risk for patients with OA of developing comor-
bidities and the biologic plausibility of such comorbidities is not 
well investigated. Of the 42 studies included, only 12 primarily 
Figure 3. Prevalence (%) of comorbidities in individuals with osteoarthritis (disease and system specific). n = number of studies; N = number 
of participants; COPD = chronic obstructive pulmonary disease. Color figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/doi/10.1002/acr.24008/abstract.
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examined the comorbidity in OA, 15 had a comparative group, 
and 27 were published in the years 2010–2017. This summary 
indicates the quality of the evidence and growing interest in OA 
comorbidity. Evidence on the risk of having disease- specific 
comorbidities is not well documented, except for hypertension, 
diabetes mellitus, and heart diseases, and these comorbidi-
ties are further less reported according to the system (61). Few 
studies are available to explain the association. For example, 
a meta- analysis done by Wang et  al (9) on the association of 
OA with cardiovascular diseases reported an association with a 
risk ratio of 1.24, which is less than in our study. Strong asso-
ciations with other generalized and localized musculoskeletal 
conditions appeared evident (74,75), but whether coexistence 
with respiratory diseases was independent or related was con-
sidered inconclusive (76), in contrast to our result. According to 
Parkinson et al (77), individuals with OA are at a 1.41 times higher 
risk of getting diabetes mellitus. Nearly one- fifth of OA patients 
have depression (11,78), but previous systematic reviews have 
been inconclusive about the extent of an association (11). We 
report risks of 11 comorbidities among patients with OA, which 
is more comprehensive than any previous study to date.
Exploring factors for comorbidities can be difficult because 
OA might share different common risk factors with different dis-
eases. The presence of multiple comorbidities could be explained 
by aging, an important risk factor for OA and other chronic con-
ditions, but we found positive associations in age- matched 
comparative studies. Associations of OA with gastrointestinal 
diseases are well documented and usually attributed to long- 
term use of analgesics, particularly nonsteroidal antiinflammatory 
drugs (NSAIDs) (79,80). We found nonuniform recording of symp-
tomatic gastrointestinal disorders by the studies, which necessi-
tates correct diagnosis and reporting among patients with OA. 
The coexistence of cardiovascular comorbidities could be due 
to shared risk factors such as obesity and metabolic syndrome 
(81,82). Besides these, NSAIDs and impaired physical activi-
ties in OA have been reported to increase risks of  developing 
 car diovascular disease (82–85). Nevertheless, the causal asso-
ciation between OA and cardiovascular disease is not well 
understood and could in part be attributable to a genetic linkage 
(86- 88). For the association of OA with depression, we hypoth-
esized that the chronicity of the disease, pain, repeated health 
care utilization, health expenditure, and functional limitation could 
be the drivers of depression among individuals having OA, and 
depression can also influence pain experience (78). Endocrine 
disorders such as hypothyroidism and diabetes mellitus could 
have an association with OA at specific joint sites (89), but a lack 
of joint- specific information and endocrine conditions in many 
studies limits our findings. We did not find fair evidence for mus-
culoskeletal comorbidities in OA, even though we found reports 
of similar age- related changes in other joints (90) or muscle 
weakness or injury causing biomechanical derangement leading 
to pain (91). The increased reporting of back pain and migraine 
among patients with both symptomatic OA and asymptomatic 
OA might reflect multiple regional pain resulting from altered pain 
physiology and central pain mechanisms (92).
Although we estimated the pooled prevalence, it needs 
careful interpretation owing to the large heterogeneity. How-
ever, this is only a systematic review of the current literature, 
and the purpose of the review is to identify a signal for future 
research, not to confirm the prevalence and the risk ratio. 
Prevalence reported in epidemiologic studies is determined by 
the study design, sample size, case definition, and diagnos-
tic method. The reported prevalence as per the system and 
disease indicates the existing burden of other chronic con-
ditions in OA, which might affect care. Most of the chronic 
conditions are age related, and thus understanding their coex-
istence across the age groups could have been helpful. How-
ever, because of the limited articles available, we could not 
perform such subgroup analysis, and we limited our discus-
sion to the association only. The heterogeneity of the studies 
Figure 4. Risk of having comorbidities among individuals with osteoarthritis compared to individuals without osteoarthritis. Only information 
on systemic comorbidities has been used from the study by Saltzman et al (35) in all estimates. M-H = Mantel-Haenszel; 95% CI = 95% 
confidence interval; NOS = Newcastle-Ottawa Scale. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/acr.24008/abstract.
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and the limited research highlight the need for better- quality 
comorbidity research in OA.
There are several limitations to this study. First, since 
multi morbidity/comorbidity in OA is not well indexed in literature 
databases, we may have omitted some studies. Second, het-
erogeneity in the prevalence estimates observed in our review, 
stemming from diversity of methodologies, may have caused 
uncertainty of the results. Third, there was ambiguity in disease 
definitions, which creates uncertainty, for example over whether 
peptic ulcer, gastritis, and acidity should be considered sepa-
rate entities. Fourth, suboptimal information about OA reported 
in studies made it difficult to differentiate between structural OA 
and symptomatic OA and to determine whether associations 
were linked primarily with structural OA or with pain experi-
ence. Similarly, the count of chronic conditions and the defini-
tion used varied considerably between studies and may have 
influenced the estimates (93). Our comparative groups included 
any non- OA cases, so the comorbidity pattern might have been 
different because of the selection of comparative/control groups, 
which needs to be interpreted with caution. Furthermore, the 
unavailability of joint- specific OA within comparative studies lim-
ited the estimation of joint- specific comorbidities. The study also 
compiles data from different study designs and thus has limita-
tions for understanding the time sequences of OA with comor-
bidities. Unfortunately, there were not enough studies in each 
subgroup (only 1 in the cohort design) in comparative studies to 
perform subgroup analysis as per the study design.
In conclusion, individuals with OA are 1.2 times more likely to 
have any comorbidity than non- OA controls and 2.5 times more 
likely to have ≥3 comorbidities. The comorbidities with the high-
est increase in risk are stroke, peptic ulcer, hypertension, and 
depression. Further research is needed to determine the causality 
between OA and these common comorbidities to optimize treat-
ment and develop preventive strategies.
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